法国疫苗制造商Moderna首席执行官Stéphane Bancel表示公司预计2025年销售额将增加，该公司股价上涨超过11%。 Moderna, a French vaccine manufacturer, saw a more than 11% increase in share price after CEO Stéphane Bancel stated that the company anticipates increasing sales in 2025.

Moderna 首席执行官 Stéphane Bancel 在一封股东信中表示，公司预计 2025 年销售额将增长，此后股价飙升逾 11%。 Moderna shares surged more than 11% after CEO Stéphane Bancel said in a shareholder letter that the company expects its sales to grow in 2025. 预计这一增长是由于该公司将于 2024 年推出 RSV 候选疫苗，并可能最早于 2025 年推出流感/新冠肺炎联合疫苗。 The growth is expected due to the launch of the company's RSV vaccine candidate in 2024 and the potential launch of a flu/COVID combination vaccine as early as 2025.